Oncology Reviews (Jul 2019)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

  • Amrallah A. Mohammed,
  • Hanaa Rashied,
  • Fifi Mostafa Elsayed

DOI
https://doi.org/10.4081/oncol.2019.416
Journal volume & issue
Vol. 13, no. 2

Abstract

Read online

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

Keywords